HIV/AIDS Clinical Trials

Showing 1281-1300 of 1,802 trials

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."

NCT02196064

To evaluate the incidence of grade 3 or 4 transaminase elevations or grade 4 total bilirubin elevations (hepatic toxicity) during the first 48 weeks of antiretroviral therapy with the combination of rilpivirine (25mg), tenofovir (245mg) and emtricitabine (200mg), in a single-tablet regimen (Eviplera®) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected subjects.

Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects

Fundación Pública Andaluza Progreso y Salud519 participantsStarted May 2014

Seville, Sevilla, Spain

COMPLETEDPhase 2

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147

A prospective, randomized, open-label pilot study to assess virologic suppression and immunologic recovery associated with a two-drug antiretroviral regimen of Raltegravir and the protease inhibitor lopinavir/ritonavir (LPV/r) and a three drug regimen with Raltegravir and two nRTIs (emtricitabine/tenofovir) in HIV-1 infected treatment-naïve subjects. Immunology Substudy added to determine the kinetics of recovery of CD4 T cells and subpopulations (regulatory T cell \[T regs\], TH-17 and TH1) after treatment initiation with Raltegravir based regimens and their relationship with functional CD8 T cells and if Raltegravir containing therapies leads to decreases in markers of gut microbial translocation and of cellular and soluble markers of immune activation.

HIV Infections

Margaret A. Fischl, M.D.44 participantsStarted Apr 2008

Miami, Florida, United States

COMPLETEDPhase 1

Drug Drug Interaction of BI 201335 and Tenofovir

NCT01340196

The objective of this study is to evaluate the drug-drug interaction potential between BI 201335 and concomitantly administered tenofovir which is used in treatment regimens for HIV infection and/or Hepatitis B infection. Results of this study will serve as a basis for guidance of dose adjustments or other precautionary measures when BI201335 and tenofovir are coadministered.

HIV Infections

Boehringer Ingelheim16 participantsStarted Apr 2011

Buffalo, New York, United States

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

Drug Drug Interaction of BI 201335 and Tenofovir

Related Searches

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals

Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

Stocrin Re-examination Study (0831-028)

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Demand Creation for Couples' HIV Counseling and Testing

Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Tissue Drug Levels of HIV Medications

HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, China

Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families

Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV

Antiviral Therapy and HIV in the Female Genital Tract